A citation-based method for searching scientific literature

Satoshi Morita, Kentaro Sakamaki, Guosheng Yin. J Natl Cancer Inst 2015
Times Cited: 16







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Detecting an overall survival benefit that is derived from progression-free survival.
Kristine R Broglio, Donald A Berry. J Natl Cancer Inst 2009
344
62

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
Volker Heinemann, Sebastian Stintzing, Dominik P Modest, Clemens Giessen-Jung, Marlies Michl, Ulrich R Mansmann. Eur J Cancer 2015
103
18

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt,[...]. Lancet Oncol 2014
18



Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
Hubert Piessevaux, Marc Buyse, Michael Schlichting, Eric Van Cutsem, Carsten Bokemeyer, Steffen Heeger, Sabine Tejpar. J Clin Oncol 2013
154
18


Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Tomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, George Sledge, James Carmichael, Hans-Joachim Lück, John R Mackey, Jean-Marc Nabholtz, Robert Paridaens, Laura Biganzoli,[...]. J Clin Oncol 2008
245
18

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Michel Ducreux, Jaafar Bennouna, Mohamed Hebbar, Marc Ychou, Gérard Lledo, Thierry Conroy, Antoine Adenis, Roger Faroux, Christine Rebischung, Loic Bergougnoux,[...]. Int J Cancer 2011
104
12

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi,[...]. N Engl J Med 2014
581
12

Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
Clemens Giessen, Ruediger Paul Laubender, Donna Pauler Ankerst, Sebastian Stintzing, Dominik Paul Modest, Ulrich Mansmann, Volker Heinemann. Clin Cancer Res 2013
48
12

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky,[...]. N Engl J Med 2009
12

Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
C Louvet, A de Gramont, C Tournigand, P Artru, F Maindrault-Goebel, M Krulik. Cancer 2001
61
12

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini,[...]. J Clin Oncol 2007
765
12

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem,[...]. N Engl J Med 2013
12

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren,[...]. N Engl J Med 2004
12

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera,[...]. J Clin Oncol 2008
12

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
John M L Ebos, Robert S Kerbel. Nat Rev Clin Oncol 2011
490
12

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Qian Shi, Aimery de Gramont, Axel Grothey, John Zalcberg, Benoist Chibaudel, Hans-Joachim Schmoll, Matthew T Seymour, Richard Adams, Leonard Saltz, Richard M Goldberg,[...]. J Clin Oncol 2015
70
12

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Steven R Alberts. J Clin Oncol 2004
12

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Daniel J Sargent, Harry S Wieand, Daniel G Haller, Richard Gray, Jacqueline K Benedetti, Marc Buyse, Roberto Labianca, Jean Francois Seitz, Christopher J O'Callaghan, Guido Francini,[...]. J Clin Oncol 2005
464
12

Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.
Takeshi Terashima, Tatsuya Yamashita, Noboru Takata, Hidetoshi Nakagawa, Tadashi Toyama, Kuniaki Arai, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi,[...]. Hepatol Res 2016
41
12

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
S Michiels, L Pugliano, S Marguet, D Grun, J Barinoff, D Cameron, M Cobleigh, A Di Leo, S Johnston, G Gasparini,[...]. Ann Oncol 2016
24
12

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
Xavier Paoletti, Koji Oba, Yung-Jue Bang, Harry Bleiberg, Narikazu Boku, Olivier Bouché, Paul Catalano, Nozomu Fuse, Stefan Michiels, Markus Moehler,[...]. J Natl Cancer Inst 2013
56
12


Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Maria Reig, Jordi Rimola, Ferran Torres, Anna Darnell, Carlos Rodriguez-Lope, Alejandro Forner, Neus Llarch, José Ríos, Carmen Ayuso, Jordi Bruix. Hepatology 2013
170
12

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
12

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
793
12

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
12

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
Brian Hutton, Georgia Salanti, Deborah M Caldwell, Anna Chaimani, Christopher H Schmid, Chris Cameron, John P A Ioannidis, Sharon Straus, Kristian Thorlund, Jeroen P Jansen,[...]. Ann Intern Med 2015
12



Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, Adrian Cook, Nozomu Yanaihara, Anna Tinker, Gunnar Kristensen, Petronella B Ottevanger, Gerasimos Aravantinos, Austin Miller,[...]. JAMA Netw Open 2020
14
14

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Agostino Ponzetti, Chiara Cremolini, Alessio Amatu, Calogero Lauricella,[...]. Nat Med 2015
489
6

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Marta Pàez-Ribes, Elizabeth Allen, James Hudock, Takaaki Takeda, Hiroaki Okuyama, Francesc Viñals, Masahiro Inoue, Gabriele Bergers, Douglas Hanahan, Oriol Casanovas. Cancer Cell 2009
6

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.
Sarah J Conley, Elizabeth Gheordunescu, Pramod Kakarala, Bryan Newman, Hasan Korkaya, Amber N Heath, Shawn G Clouthier, Max S Wicha. Proc Natl Acad Sci U S A 2012
444
6

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Shintaro Takeuchi, Muhammad Baghdadi, Takahiro Tsuchikawa, Haruka Wada, Toru Nakamura, Hirotake Abe, Sayaka Nakanishi, Yuu Usui, Kohtaro Higuchi, Mizuna Takahashi,[...]. Cancer Res 2015
72
6

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
G Masi, L Marcucci, F Loupakis, E Cerri, C Barbara, S Bursi, G Allegrini, I M Brunetti, R Murr, S Ricci,[...]. Ann Oncol 2006
22
6

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, T Di Desidero, B Canu, M Schirripa, P Frumento,[...]. Br J Cancer 2011
77
6

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Gemma Bruera, Alessandra Santomaggio, Katia Cannita, Paola Lanfiuti Baldi, Marianna Tudini, Federica De Galitiis, Maria Mancini, Paolo Marchetti, Adelmo Antonucci, Corrado Ficorella,[...]. BMC Cancer 2010
35
6


Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
E Bajetta, L Celio, E Ferrario, M Di Bartolomeo, A Denaro, K Dotti, M Mancin, R Bajetta, A Colombo, S Pusceddu. Ann Oncol 2007
28
6

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Gianluca Masi, Fotios Loupakis, Luca Pollina, Enrico Vasile, Samanta Cupini, Sergio Ricci, Isa Maura Brunetti, Roberta Ferraldeschi, Giuseppe Naso, Franco Filipponi,[...]. Ann Surg 2009
158
6

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Gunnar Folprecht, Thomas Gruenberger, Wolf O Bechstein, Hans-Rudolf Raab, Florian Lordick, Jörg T Hartmann, Hauke Lang, Andrea Frilling, Jan Stoehlmacher, Jürgen Weitz,[...]. Lancet Oncol 2010
613
6

Cancer statistics, 2014.
Rebecca Siegel, Jiemin Ma, Zhaohui Zou, Ahmedin Jemal. CA Cancer J Clin 2014
6


Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Gunnar Folprecht, Susanne Hamann, Katharina Schütte, Tanja Trarbach, Jan Stoehlmacher-Williams, Gerhard Ehninger. BMC Cancer 2014
27
6

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
E Raymond, C Buquet-Fagot, S Djelloul, J Mester, E Cvitkovic, P Allain, C Louvet, C Gespach. Anticancer Drugs 1997
210
6


Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Gianluca Masi, Enrico Vasile, Fotios Loupakis, Samanta Cupini, Lorenzo Fornaro, Giacomo Baldi, Lisa Salvatore, Chiara Cremolini, Irene Stasi, Isa Brunetti,[...]. J Natl Cancer Inst 2011
105
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.